Boston Scientific Corp. (BSX) Tops Q1 EPS by 7c; Guides EPS Above the Street
Get Alerts BSX Hot Sheet
Price: $45.29 +0.76%
EPS Growth %: +10.7%
Financial Fact:
Royalty expense: 20M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +10.7%
Financial Fact:
Royalty expense: 20M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Boston Scientific Corp. (NYSE: BSX) reported Q1 adjusted-EPS of $0.15, $0.07 better than the analyst estimate of $0.08. Revenue for the quarter came in at $1.87 billion versus the consensus estimate of $1.86 billion.
Boston Scientific Corp. sees Q2 2012 adjusted EPS of $0.14-$0.17, versus the consensus of $0.10. Boston Scientific Corp. sees Q2 2012 revenue of $1.85-$1.95 billion, versus the consensus of $1.9 billion.
Boston Scientific Corp. sees adjusted FY2012 EPS of $0.60-$0.70, versus the consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.35-$7.65 billion, versus the consensus of $7.48 billion.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q2 2012 adjusted EPS of $0.14-$0.17, versus the consensus of $0.10. Boston Scientific Corp. sees Q2 2012 revenue of $1.85-$1.95 billion, versus the consensus of $1.9 billion.
Boston Scientific Corp. sees adjusted FY2012 EPS of $0.60-$0.70, versus the consensus of $0.42. Boston Scientific Corp. sees FY2012 revenue of $7.35-$7.65 billion, versus the consensus of $7.48 billion.
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
- Pfizer reafffirms 2026 guidance after CFO transition announcement
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share